

S3 Table. Types of second-line treatments in patients with no evidence of T790M after afatinib

	No. (%)
Pemetrexed-platinum doublet	74 (33.3)
Pemetrexed monotherapy	74 (33.3)
gemcitabine-platinum doublet	33 (14.9)
Gefitinib	12 (5.4)
Erlotinib	6 (2.7)
Gemcitabine	3 (1.4)
Etoposide-platinum doublet	4 (1.8)
Paclitaxel-platinum doublet	2 (0.9)
Erlotinib+Capmatinib	1 (0.5)
Nivolumab+Ipilimumab	1 (0.5)
Nivolumab	2 (0.9)
Bevacizumab	1 (0.5)
Olmotinib	1 (0.5)
Crizotinib	2 (0.9)
Atezolizumab+Bevacizumab+Paclitaxel+Carboplatin	1 (0.5)
Pembrolizumab+Pemetrexed+Carboplatin	1 (0.5)
Afatinib+Xentuzumab	2 (0.9)
Lazertinib	2 (0.9)